PRDX1 (Peroxiredoxin 1)

PRDX1 (Peroxiredoxin 1)

Overview

PRDX1 (Peroxiredoxin 1) is a member of the peroxiredoxin family of antioxidant proteins that catalyze the reduction of hydrogen peroxide (H₂O₂), organic hydroperoxides, and peroxynitrite. As one of the most abundant cellular proteins, PRDX1 plays critical roles in antioxidant defense, redox signaling, and molecular chaperone activity. Its function is particularly vital in the brain, where oxidative stress is a hallmark of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/als).[@park2021]

Peroxiredoxins represent an evolutionarily conserved family of peroxidases that were first discovered in yeast and subsequently characterized across all kingdoms of life.[@ishii2010] PRDX1, originally identified as "natural killer-enhancing factor B" (NKEF-B), has emerged as a central player in cellular redox homeostasis and has been extensively studied in the context of neurodegeneration.

PRDX1 (Peroxiredoxin 1)

Overview

PRDX1 (Peroxiredoxin 1) is a member of the peroxiredoxin family of antioxidant proteins that catalyze the reduction of hydrogen peroxide (H₂O₂), organic hydroperoxides, and peroxynitrite. As one of the most abundant cellular proteins, PRDX1 plays critical roles in antioxidant defense, redox signaling, and molecular chaperone activity. Its function is particularly vital in the brain, where oxidative stress is a hallmark of neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/als).[@park2021]

Peroxiredoxins represent an evolutionarily conserved family of peroxidases that were first discovered in yeast and subsequently characterized across all kingdoms of life.[@ishii2010] PRDX1, originally identified as "natural killer-enhancing factor B" (NKEF-B), has emerged as a central player in cellular redox homeostasis and has been extensively studied in the context of neurodegeneration.

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">PRDX1 (Peroxiredoxin 1)</th>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Peroxiredoxin 1</td>
</tr>
<tr>
<td class="label">Gene</td>
<td>[PRDX1](/genes/prdx1)</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q06830" target="_blank">Q06830</a></td>
</tr>
<tr>
<td class="label">PDB ID</td>
<td>1XCC, 2ZYL, 1QQ7</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>22 kDa (199 amino acids)</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytosol, Nucleus, extracellular (secreted)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Peroxiredoxin family (2-Cys typical)</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Ubiquitous, highest in brain, liver, kidney</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/infection" style="color:#ef9a9a">Infection</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">119 edges</a></td>
</tr>
</table>

Structure and Biochemistry

Protein Architecture

PRDX1 is a homodimeric protein with each subunit comprising approximately 199 amino acids. The protein adopts a typical 2-Cys peroxiredoxin fold characterized by:

• N-terminal region: Contains the resolving cysteine (Cys⁵¹) critical for catalytic activity
• C-terminal region: Harbors the peroxidatic cysteine (Cys¹⁷²) that initiates the peroxide reduction reaction
• Conserved FFYPGW motif: Located in the active site pocket, essential for substrate binding
• Decameric assembly: At high concentrations, PRDX1 dimers associate into ring-like decamers (10-mers) that enhance its chaperone activity

Catalytic Mechanism

PRDX1 catalyzes peroxide reduction through a conserved mechanism involving two reactive cysteine residues:

This catalytic cycle allows PRDX1 to neutralize hydrogen peroxide efficiently, preventing oxidative damage to proteins, lipids, and DNA. Unlike catalase or glutathione peroxidase, PRDX1 operates at low peroxide concentrations and plays a central role in redox signaling rather than gross peroxide detoxification.

Oligomerization States

PRDX1 exhibits remarkable structural plasticity, existing in multiple oligomeric states:

• Dimer: The fundamental functional unit (≈44 kDa)
• Decamer: Ten monomers arranged in a toroidal structure (≈220 kDa), formed at high protein concentrations or under oxidative stress
• Hyperoxidized forms: Upon exposure to high H₂O₂, the catalytic cysteine can be hyperoxidized to sulfinic (Cys-SO₂) or sulfonic (Cys-SO₃) forms, temporarily inactivating peroxidase activity while enhancing chaperone function

Biological Functions

Antioxidant Defense

PRDX1 serves as a primary line of defense against oxidative stress in neuronal cells. Its functions include:

Hydrogen peroxide scavenging: PRDX1 reduces H₂O₂ to water with high efficiency (kcat ≈ 10⁵ M⁻¹s⁻¹), protecting neurons from ROS-induced damage. This is particularly important in the brain, which consumes 20% of oxygen yet constitutes only 2% of body weight, making it inherently vulnerable to oxidative stress.

Lipid peroxidation prevention: By reducing organic hydroperoxides (e.g., lipid hydroperoxides), PRDX1 protects neuronal membranes from peroxidation damage that contributes to neurodegeneration.

DNA protection: PRDX1 localizes to the nucleus and protects DNA from oxidative damage, important for neuronal genomic stability.

Redox Signaling

Beyond simple antioxidant function, PRDX1 participates in sophisticated redox signaling pathways:

H₂O₂ as a second messenger: At physiological concentrations, H₂O₂ acts as a signaling molecule regulating various processes including cell proliferation, differentiation, and stress responses. PRDX1 modulates H₂O₂ levels to ensure appropriate signaling while preventing damage.

Interaction with transcription factors: PRDX1 interacts with and regulates key transcription factors including:

• NF-κB: PRDX1 suppresses NF-κB signaling by inhibiting IKK kinase activity, reducing pro-inflammatory gene expression
• Nrf2: PRDX1 regulates Nrf2-ARE pathway activation, coordinating the antioxidant response
• STAT3: PRDX1 can modulate JAK-STAT signaling pathways

Molecular Chaperone Activity

Under conditions of severe oxidative stress, PRDX1 transitions from an enzyme to a molecular chaperone:

• The decameric form binds to unfolding proteins, preventing their aggregation
• Hyperoxidized PRDX1 exhibits enhanced chaperone activity
• This function is particularly important in neurodegenerative diseases where protein aggregation is a core pathological feature

Regulation of Cell Death

PRDX1 plays complex roles in regulating apoptosis and necrosis:

Anti-apoptotic function: PRDX1 inhibits various apoptotic pathways:

• Suppresses cytochrome c release from mitochondria
• Inhibits caspase activation
• Blocks ASK1-JNK signaling cascade

Role in Neurodegenerative Diseases

Alzheimer's Disease

PRDX1 is profoundly affected in [Alzheimer's disease](/diseases/alzheimers-disease), with both expression changes and post-translational modifications observed:

Expression alterations: Multiple studies have documented increased PRDX1 expression in AD brain, representing a compensatory response to heightened oxidative stress. However, this elevated PRDX1 becomes progressively inactivated through hyperoxidation, reducing its protective capacity.

Oxidative modification: Cumming et al. (2004) first demonstrated that PRDX1 is oxidatively modified in AD brain, with increased levels of the disulfide-bonded form indicating functional impairment.

Relationship to Aβ pathology: PRDX1 interacts with amyloid-beta (Aβ) peptides:

• Aβ can induce oxidative stress that consumes PRDX1
• PRDX1 can protect neurons from Aβ-induced toxicity
• The peroxiredoxin system is overwhelmed in advanced AD

• Nrf2 activators that upregulate PRDX1 expression
• Small molecules that prevent PRDX1 hyperoxidation
• Gene therapy to increase PRDX1 levels

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), PRDX1 plays critical protective roles, particularly in dopaminergic neurons:

Protective function in dopaminergic neurons: Yang et al. (2009) demonstrated that PRDX1 protects dopaminergic neurons from oxidative stress-induced cell death through multiple mechanisms:

• Direct neutralization of ROS
• Preservation of mitochondrial function
• Inhibition of apoptotic pathways

• α-Synuclein: PRDX1 can reduce oxidative modification of α-synuclein, potentially limiting its aggregation propensity
• Parkin: The E3 ubiquitin ligase Parkin, mutated in autosomal recessive PD, may regulate PRDX1 degradation
• PINK1: The kinase PINK1, also mutated in familial PD, affects PRDX1 phosphorylation status

Therapeutic development: PRDX1-based therapeutics for PD include:

• Recombinant PRDX1 protein delivery
• Gene therapy vectors encoding PRDX1
• Small molecule activators of the PRDX1 promoter

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/als), PRDX1 alterations contribute to disease progression:

Oxidative stress marker: Elevated PRDX1 levels in CSF and brain tissue serve as biomarkers of oxidative stress in ALS.

Mutual TDP-43 relationship: The RNA-binding protein TDP-43, which forms characteristic inclusions in ALS, may regulate PRDX1 expression. Conversely, PRDX1 deficiency accelerates TDP-43 pathology in model systems.

SOD1 interactions: In SOD1-linked familial ALS, PRDX1 may interact with mutant SOD1 aggregates, potentially contributing to the oxidative stress burden.

Therapeutic targeting: Strategies to enhance PRDX1 function in ALS include:

• Antioxidant combinatorial therapies
• Nrf2 pathway activation
• Gene therapy approaches

Other Neurodegenerative Conditions

Huntington's disease: PRDX1 expression is altered in HD brain, with implications for mitochondrial function and mutant huntingtin aggregation.

Multiple sclerosis: PRDX1 serves as both a biomarker and therapeutic target in demyelinating diseases.

Stroke and traumatic brain injury: PRDX1 is upregulated in response to acute brain injury, where it limits oxidative damage.

Therapeutic Implications

Targeting PRDX1 for Neurodegeneration

Given its central role in oxidative stress defense, PRDX1 represents an attractive therapeutic target:

Upregulation strategies:

• Nrf2 activators: Compounds like sulforaphane, bardoxolone methyl, and dimethyl fumarate activate Nrf2-ARE pathway, dramatically increasing PRDX1 expression
• Epigenetic modulators: HDAC inhibitors can upregulate PRDX1 transcription
• Gene therapy: AAV-mediated PRDX1 delivery to CNS is under investigation

• Thioredoxin system support: Enhancing thioredoxin reductase activity improves PRDX1 recycling
• Hyperoxidation prevention: Sulfiredoxin (SRX) inhibitors are being developed to prevent PRDX1 inactivation

• Recombinant PRDX1: Purified protein for intravenous or intrathecal delivery
• Cell-penetrating derivatives: TAT-PRDX1 and similar fusion proteins for neuronal delivery

Challenges and Considerations

Blood-brain barrier: Therapeutic delivery of PRDX1 to the CNS remains challenging; novel approaches including intranasal delivery and BBB-modulating agents are under investigation.

Optimal dosing: Too much PRDX1 activity may interfere with physiological redox signaling; precise dosing regimens are needed.

Biomarker development: PRDX1 levels in CSF or blood may serve as biomarkers for patient selection and treatment response.

Genetic Regulation

Transcriptional Control

PRDX1 expression is regulated at the transcriptional level by multiple factors:

• Nrf2-ARE pathway: The primary regulator, with functional antioxidant response elements (ARE) in the PRDX1 promoter
• p53: Can activate PRDX1 transcription under genotoxic stress
• AP-1: Positive regulation in response to growth factors and stress
• SP1: Constitutive expression through GC-rich promoter elements

Post-Transcriptional Regulation

PRDX1 is also regulated at the post-transcriptional level:

• MicroRNAs: miR-200 family members can target PRDX1 mRNA
• Alternative splicing: Generates PRDX1 isoforms with distinct properties
• mRNA stability: AU-rich elements in 3' UTR affect mRNA half-life

Interactions and Pathways

Protein-Protein Interactions

PRDX1 interacts with numerous proteins, forming a network relevant to neurodegeneration:

| Partner | Interaction Type | Functional Consequence |
|---------|------------------|------------------------|
| Thioredoxin (TXN) | Substrate | Enzyme reduction/regeneration |
| Thioredoxin reductase | Indirect | Provides reducing equivalents |
| ASK1 | Inhibition | Blocks pro-apoptotic signaling |
| NF-κB (p65) | Inhibition | Reduces inflammation |
| p53 | Stabilization | Modulates DNA damage response |
| α-Synuclein | Binding | May reduce aggregation |
| TDP-43 | Interaction | Modifies ALS pathology |

Signaling Pathways

PRDX1 participates in several critical signaling pathways:

Antioxidant response: Nrf2 → PRDX1 → cellular defense genes Apoptosis regulation: PRDX1 → ASK1/JNK → cell survival Inflammation: PRDX1 → NF-κB → pro-inflammatory cytokines Redox signaling: ROS → PRDX1 oxidation → adaptive response

Animal Models

Knockout Mice

PRDX1-deficient mice exhibit:

• Enhanced sensitivity to oxidative stress
• Accelerated neurodegeneration in disease models
• shortened lifespan
• Cancer predisposition (due to p53 hyperactivation)

Transgenic Overexpression

PRDX1 transgenic mice show:

• Reduced oxidative damage in brain
• Protection against MPTP-induced Parkinsonism
• Improved cognitive function in aging
• Reduced Aβ toxicity in AD models

Disease Model Studies

• MPTP model of PD: PRDX1 overexpression protects dopaminergic neurons
• Aβ model of AD: PRDX1 reduction correlates with cognitive deficits
• SOD1 model of ALS: PRDX1 levels predict disease progression

Biomarker Potential

Cerebrospinal Fluid

PRDX1 levels in CSF serve as:

• Biomarker of oxidative stress in neurodegenerative diseases
• Potential diagnostic tool for early disease detection
• Indicator of treatment response in clinical trials

Blood-Based Testing

Peripheral PRDX1 measurements:

• Less invasive than CSF collection
• Correlate with disease severity in some conditions
• Require further validation for clinical use

Research Directions

Current Knowledge Gaps

Several aspects of PRDX1 biology remain incompletely understood:

• Precise mechanisms of PRDX1 release from cells
• Role of extracellular PRDX1 in neurodegeneration
• Optimal therapeutic modulation strategies
• Patient selection criteria for PRDX1-targeted therapies

Emerging Research Areas

• PRDX1 in synapse function: New data suggest roles in synaptic plasticity
• PRDX1 in neuroinflammation: Interaction with microglial activation states
• PRDX1 in circadian regulation: Connections to daily oxidative stress rhythms
• PRDX1 in epigenetic regulation: Effects on DNA methylation patterns

Conclusion

PRDX1 stands as a critical defender against oxidative stress in the nervous system, with protective roles in multiple neurodegenerative diseases. Its dual function as a peroxidase and molecular chaperone makes it uniquely positioned to combat the proteostatic and oxidative stress that characterize Alzheimer's, Parkinson's, and related conditions. Understanding and targeting PRDX1 offers promising therapeutic opportunities, though significant challenges remain in translating basic research into clinical applications.

As the field progresses, PRDX1-based therapies may become part of combination approaches that address multiple pathological mechanisms simultaneously—an essential strategy given the complex nature of neurodegenerative diseases.

References

See Also

• [Peroxiredoxin Family](/proteins/peroxiredoxin-family)
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-neurodegeneration)
• [Alzheimer's Disease Antioxidant Pathways](/diseases/alzheimers-disease)
• [Parkinson's Disease Mechanisms](/diseases/parkinsons-disease)
• [Nrf2-ARE Signaling Pathway](/mechanisms/nrf2-are-signaling)
• [Mitochondrial Dysfunction in Neurodegeneration](/mechanisms/mitochondrial-dysfunction-neurodegeneration)

External Links

• [UniProt: PRDX1](https://www.uniprot.org/uniprot/Q06830)
• [PDB: PRDX1 Structure](https://www.rcsb.org/structure/1XCC)
• [PubMed: Peroxiredoxin 1](https://pubmed.ncbi.nlm.nih.gov/?term=PRDX1+peroxiredoxin+neurodegeneration)